Ozempic, Mounjaro and the Mind: What Happens Beyond Weight

Ask someone a month into treatment what has changed, and the answer is usually not about the weighing scale. It is that the thinking has stopped.

Researchers have started calling this food noise, and in the last two years it has moved from a word patients used to a term with a formal definition: persistent thoughts about food that the person experiences as unwanted or distressing, closer to rumination than to ordinary hunger. There is now a validated questionnaire for it. For people who have spent decades negotiating with themselves about what they will eat later, its disappearance is often described as relief rather than as weight loss.

Two honest caveats. No randomised trial has yet used one of these new instruments to demonstrate that the drugs reduce food noise, so the claim rests on what patients consistently report rather than on trial data. And in the qualitative studies that do exist, the relief is described as a reduced mental burden, not as feeling less alive.

Where all this happens in the brain is less settled than popular accounts suggest. In rodents these drugs clearly act on the reward circuitry of the midbrain. In primates and humans the receptors are concentrated in the hypothalamus, the brainstem and the amygdala rather than in the classic dopamine reward centres, and no human study has ever measured brain dopamine before and after treatment. The appetite effect is not in doubt. The neat story about the drug reaching into the pleasure system is an inference, not a finding.

For a while these medicines carried a warning about suicidal thoughts, and it frightened a lot of people. It is worth knowing that the warning was never based on evidence from these drugs. It was carried over from older weight-loss medicines.

In January 2026 the US Food and Drug Administration asked for it to be removed from the three weight-loss products that carried it, after reviewing 91 placebo-controlled trials involving 107,910 participants and a separate study of more than 2.2 million people. Neither found an increased risk of suicidal thoughts or behaviour, nor of depression, anxiety, irritability or psychosis. Europe's drug safety committee had already reached the same conclusion in April 2024.

Two further pieces of evidence point the same way. A 2025 review in JAMA Psychiatry pooled 80 placebo-controlled trials covering 107,860 people and found no difference from placebo in psychiatric side effects or in depressive symptoms, alongside improvements in mental health quality of life. And a 2026 Swedish national study following 95,490 people who already had depression or anxiety found that those on semaglutide were, if anything, less likely to deteriorate than during periods when they were not taking it.

That is a genuinely reassuring body of evidence, and anyone who tells you these drugs cause depression is arguing against it. But it answers one question, not every question.

A smaller number of people describe something they find hard to name. Not sadness, not low mood in the usual sense, but a dulling. Things that used to be interesting are merely fine. Music that used to move them does not. They are not distressed so much as absent.

In psychiatry the word for reduced capacity to feel pleasure and interest is anhedonia. It is a core feature of depression, but it can occur without depression, and it is what people are usually reaching for when they say they feel flat.

Here is the honest position on whether these drugs cause it.

The published evidence amounts to one case series of three patients, published in 2026, describing reduced motivation and emotional flatness on high-dose tirzepatide that improved when the dose was lowered. In one of the three, raising the dose brought the symptoms back and lowering it again resolved them, which is the kind of sequence that makes a clinician take notice. That is the entirety of the formal evidence. Three people, no control group, no anhedonia rating scale used.

Against that, the large trials found nothing. But this is where a careful reader should slow down. No trial of these drugs has ever administered an anhedonia scale or a reward-processing task. Psychiatric side effects in those studies were captured by whatever participants happened to volunteer. Emotional blunting is something people rarely report unprompted, partly because it is difficult to describe and partly because someone who is losing weight successfully does not want to complain. Nobody asked, so nobody found it.

Five qualitative studies have interviewed people about their experience of these drugs in some depth. None of them reports a theme of emotional flattening. What they report is relief from food preoccupation, a restored sense of agency, and often self-compassion for the first time in years. That is meaningful evidence, though the studies are small and none of them asked about pleasure directly either.

So: not established, not disproved, not properly studied. Anyone stating confidently in either direction is going beyond what is known. What matters clinically is that when a real person says this is happening to them, the answer is not to argue with them about the literature. It is to work out what is actually going on, because there are several possibilities and most of them are treatable.

When someone tells me they have lost their spark since starting one of these medicines, the drug is the fourth thing I consider, not the first.

1. Are you eating enough, and eating properly? This is the most common explanation and the most fixable, and it gets missed constantly. A 2026 review of the nutrition research found that energy intake on these drugs falls by roughly a quarter to two fifths, and that protein and micronutrient intake is almost never systematically assessed. Only a handful of the studies involved a dietitian at all.

What sustained undernutrition does to the mind has been known since the 1940s, when the Minnesota starvation study documented apathy, irritability, weakness and loss of interest in almost everything among healthy young men on a severe energy deficit. Nobody on a weight-loss injection is in that state. But the direction of effect is not in question, and a person eating very little, taking in barely any protein, and losing weight quickly can feel exactly as described here for reasons that have nothing to do with the drug acting on the brain. Low iron, low vitamin B12 and low vitamin D produce the same picture and are common in India regardless.

2. What was food doing for you before? This is the question I find most useful and the one patients are least often asked.

If eating was how you managed stress, or boredom, or loneliness, or the end of a difficult day, then removing the appetite removes the coping strategy without touching the thing it was managing. What is left can feel like flatness, but it may be closer to exposure. The drug did not create an emptiness. It removed what was covering one. That is not a reason to stop treatment. It is a reason to build something else in that space, and it is ordinary psychological work with a good track record.

3. Is this actually depression? Anhedonia is one of the two core symptoms of a depressive episode. Weight loss is often undertaken at a moment when life is already difficult, and a depressive episode that would have happened anyway does not politely wait until the injections are finished. Losing interest, sleeping badly, feeling worthless, struggling to concentrate and feeling hopeless together mean something different from flatness alone, and they respond to treatment.

4. Could it be the medicine? It remains possible, and if the first three have been properly excluded, it should be discussed with the prescriber. The case series suggests that dose is worth looking at before treatment is abandoned. That decision belongs to the doctor prescribing it, in the context of everything else going on.

These drugs work by making food less compelling. In a person with a healthy relationship with eating, that is the intended effect. In a person with a history of restriction, it can be fuel.

The reassuring finding first. Binge eating tends to improve. A 2026 review of 25 trials found reduced binge eating, reduced loss-of-control eating and reduced emotional eating. A history of binge eating is not, by itself, a reason to rule these medicines out.

The same review found something else worth knowing. Dietary restraint increased. The authors were careful to say it is not clear whether that represents healthy self-regulation or the start of rigid restriction. From the outside, early on, the two look identical, and so does the praise both attract.

Specialists in this field, including the National Eating Disorders Association, take the position that very little research exists on these drugs in people with eating disorders, and that they can do harm when used without eating disorder expertise, when poorly monitored, or when the motivation is driven by shame about body size rather than by health. A 2026 paper in the International Journal of Eating Disorders makes the case for routine eating disorder screening before and during treatment. That is not a fringe view.

The distinction that matters is between eating less because food has stopped shouting, and eating less because eating has started to feel like failure. The first is the medicine working. The second is something else beginning, and it is much easier to interrupt early.

Many people report they simply stop wanting to drink, and the evidence behind this has strengthened considerably.

A 2026 trial in The Lancet randomised 108 people with alcohol use disorder and obesity to semaglutide or placebo alongside cognitive behavioural therapy for 26 weeks. Heavy drinking days fell substantially further on semaglutide than on placebo. An earlier smaller trial had already found reduced craving and reduced drinking on the days people drank. Large observational studies also report lower rates of several substance use disorders among people taking these drugs.

This is genuinely interesting and may turn out to matter. Two cautions all the same. These are trials in specific populations over months, not a licensed treatment for alcohol dependence, and the established treatments for alcohol problems remain the established treatments. And a reduced urge to drink is not the same as a resolved drinking problem. If alcohol has been holding something at bay, that something does not disappear because the drinking has.

Beyond alcohol, be careful what you believe. There is no study at all on these drugs and gambling. Claims about compulsive shopping rest on comments people have posted online. There is no evidence they reduce sexual desire, and the one published observation on the subject reports the opposite. The reward system is a plausible common thread, which is exactly why the confident claims outrun the data.

A body that changes quickly is not automatically a body that feels better to live in.

A 2026 paper in the journal Body Image makes the point plainly: how body image actually changes on these drugs has received very little systematic attention. There is no study following people before, during and after treatment. So what follows is drawn from the closest available evidence, mostly from bariatric surgery, and should be read that way.

What that research suggests is that body image usually improves, but that dissatisfaction can relocate rather than resolve. Loose skin becomes a new and specific source of distress, sufficiently so that people who want body-contouring surgery after weight loss report lower body satisfaction than those who do not. Facial volume loss is a documented consequence of rapid weight loss and is worse when protein intake is inadequate.

On muscle, one widespread claim needs correcting. It is often said that these drugs strip muscle in a way that dieting does not. A 2026 meta-analysis of 20 trials and nearly 16,000 people found that the proportion of weight lost as lean tissue on these medicines is no different from lifestyle weight loss. What differs is the total amount lost, so the absolute figure is larger. Where strength has actually been measured, it held up or improved. Adequate protein and resistance exercise remain sensible advice, for the same reasons they always were.

Then there is what other people say. A controlled study found that women who lost weight using one of these medicines were judged more harshly than women who lost the same weight through diet and exercise, because it was seen as a shortcut. Patients feel this. Several describe hiding the treatment from friends and family. Carrying a secret about your own medical care is its own quiet burden, and it is one worth naming rather than tolerating.

The deeper question is what the weight was holding. If confidence, standing at work, or the belief that you are worth someone's attention all arrive with the new body, they are resting on something that requires a weekly injection to maintain. That is worth noticing while things are going well, not after.

In the extension of a large semaglutide trial, people who stopped after 68 weeks regained about two thirds of their weight loss over the following year, and the improvements in blood pressure, blood sugar and lipids drifted back with it.

A systematic review published in the BMJ in January 2026, covering 37 studies and 9,341 people, found weight returning at roughly 0.4 kg a month after stopping weight-management medication, and faster for semaglutide and tirzepatide at about 0.8 kg a month, with weight reaching its starting point in around 1.7 years on average.

Individual paths vary and no average decides any one person's case. But in India this is not only a clinical question. These medicines are paid for out of pocket, since Indian health insurance covers hospitalisation rather than outpatient prescriptions. Cost is the commonest reason people stop, which means many people will stop for reasons that have nothing to do with whether it was working.

The psychological part is the part that goes unplanned. Weight regain after stopping an appetite-regulating medicine is a biological response, not a character failure, and it is important that people know that before it happens rather than after. It lands very differently on someone who was told to expect it than on someone who believed the change was permanent and now reads its reversal as proof of something about themselves. Appetite also returns, sometimes abruptly, and for people with a history of disordered eating that return can be genuinely frightening.

Most people who take these medicines will not need a psychiatrist, and this article should not be read as suggesting otherwise. The evidence says that on average mental health does not worsen and may improve.

There is a smaller group for whom a psychiatric opinion is genuinely useful, and it is reasonably well defined.

Anyone with a past or present eating disorder, or with a history of restriction, purging, laxative use or compulsive exercise, is better assessed before starting than after something has gone wrong. Anyone whose weight gain followed a psychiatric medicine such as olanzapine, clozapine, valproate, lithium or mirtazapine has a specific set of questions to work through, which is covered separately here. Anyone taking lithium needs closer monitoring than usual when starting. And anyone who has lost their interest in life, become frightened of eating, found that alcohol has quietly moved rather than gone, or discovered that a smaller body has not delivered what they expected of it, is describing something that psychiatry treats.

Being flat is not a side effect to be endured in exchange for weight loss. It has causes, most of which can be identified, and most of which can be addressed without giving up the treatment.